Matching-Adjusted Indirect Comparison of Amivantamab vs Mobocertinib in Platinum-pretreated EGFR Exon 20 Insertion-Mutated NSCLC - supplementary material

<b>Supplementary Methods</b><b>Supplementary Results</b><b>Supplemental Table 1.</b> Naïve and population-adjusted estimates of ORR and CBR for amivantamab: sensitivity analyses<b>Supplemental Figure 1. Histogram of the w</b>eights associated with matching in the a) base case analysis; b) adjusting for additional factors and c) using the CHRYSALIS primary efficacy population (n = 81)<b>Supplemental Figure 2. </b>Sensitivity analysis results of PFS of amivantamab versus mobocertinib a) adjusting for additional factors and b) using the CHRYSALIS primary efficacy population (n = 81)<b>Supplemental Figure 3.</b> Sensitivity analysis results of OS of amivantamab versus mobocertinib a) adjusting for additional factors and b) using the CHRYSALIS primary efficacy population (n = 81)<b>Supplemental Figure 3. </b>Sensitivity Analysis:<b> </b>Population-adjusted safety outcomes for amivantamab in the safety population (matched for an additional four factors) and mobocertinib in the PPP population<b>Supplemental Figure 4. </b>Sensitivity Analysis:<b> </b>Population-adjusted safety outcomes for amivantamab in the n = 81 population and mobocertinib in the PPP population<br>